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ABSTRACT
Background Talaporf in sodium photodynamic 
therapy (TS-PDT) for local failure after chemoradio-
therapy (CRT) in patients with esophageal squamous 
cell carcinoma has recently been reported to be highly 
effective and less invasive, compared to other treat-
ment modalities. TS-PDT was recently introduced at 
the Tottori University Hospital, Japan. The aim of this 
study is to clarify the efficacy and safety of PDT in our 
hospital.
Methods This was a single-center observational 
study. We examined eight cases of TS-PDT performed 
between January 2016 and December 2019. The main 
endpoints were local complete remission (L-CR) rate 
and the adverse events. In addition, age, gender, histol-
ogy, tumor location, TNM stage, tumor depth, irradia-
tion dose, and overall survival (OS) were examined.
Results The patients included 7 men and a woman, 
with an average age of 72.1 years (range 63–82 years). 
The baseline clinical stages before CRT or radiotherapy 
were stage I in 1, stage II in 3, stage III in 3, and stage 
IVA in 1 patient. The T stage on endoscopic assess-
ment before TS-PDT was T1 in 6 patients and T2 in 2 
patients. Treatment outcomes and adverse events were 
evaluated. There were no treatment-related deaths, and 
no significant adverse events occurred intraoperatively 
or postoperatively. The L-CR rate was 7/8 (87.5%); T1 
cases had 100% (6/6) L-CR, while T2 cases had 50% 
(1/2). The 2-year OS rates were 87%.
Conclusion TS-PDT was observed to be safe and ef-
fective in the first eight cases of its application following 
its introduction in our hospital.
Key words esophageal cancer; talaporfin sodium; 
photodynamic therapy; salvage treatment; squamous 
cell carcinoma
Esophageal cancer was the sixth most common malig-
nancy worldwide in 2018.1 Esophageal adenocarcinoma 
and esophageal squamous cell carcinoma (ESCC) 
are the two major histological subtypes of esophageal 
cancer. In Japan, ESCC is currently the most common 
subtype.2 Chemoradiotherapy (CRT) is a curative 
treatment option for ESCC.3, 4 However, local recur-
rence or residual disease without distant metastasis, 
after completion of CRT, remains a major problem.5, 6 
Salvage esophagectomy in these patients is associated 
with higher postoperative morbidity and mortality.7, 8 
Salvage endoscopic resection (ER) is a curative treat-
ment option for early ESCC with no lymph node metas-
tasis. However, in case of recurrent lesions after CRT, 
en bloc and complete resection rates of ER are relatively 
low due to severe fibrosis.9, 10
Photodynamic therapy (PDT), which induces 
tissue destruction by combining a photosensitizer and 
laser irradiation, has been developed as a less invasive 
treatment of choice for a variety of cancers including 
esophageal cancer.11, 12 There have been few previous 
reports studying the efficacy and safety of salvage 
PDT for local failure in ESCC after CRT.13, 14 Yano 
et al. reported that 76% (19/25) of patients achieved a 
local complete remission (L-CR) in a phase II study of 
salvage PDT using a combination of the first generation 
photosensitizer, porfimer sodium (PS), and excimer dye 
laser (PS-PDT) for local residual stage T1 ESCC after 
CRT.13 Yano et al. have also reported a high L-CR rate 
(88.8%) for local residual stage T1 and T2 tumors in an 
investigator-initiated trial of PDT using a combination 
of the second-generation photosensitizer, talaporfin 
sodium (TS), and diode laser (TS-PDT).14 Salvage PDT 
after local failure of CRT or radiotherapy (RT) was 
covered by the Japanese health insurance from 2015. 
We used TS-PDT in January 2016 for the first time in 
Chugoku District. Herein, we report our experience 
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regarding its safety profile and efficacy, through a case 
series.
MATERIALS AND METHODS
This was a single-center observational study. We ex-
amined eight cases of PDT performed between January 
2016 and December 2019. The indications for salvage 
PDT included all these criteria: (i) lesions limited to no 
higher than stage T2 prior to PDT, (ii) local failure after 
CRT or radiotherapy, (iii) absence of any lymph node 
or distant metastasis, (iv) no indications for ER, and (v) 
no indications for, or the patient’s refusal to undergo 
salvage surgery. The aims of this study are to clarify the 
CR rate at the primary site and the safety of PDT (adverse 
events and toxicity). The adverse events and toxicity 
were evaluated and graded according to the Common 
Terminology Criteria for Adverse Events (CTCAE) 
version 4.0.15 In addition, age, gender, treatment before 
PDT, histology, tumor location, TNM stage before PDT, 
pattern of failure, number of lesions, tumor depth, and 
irradiation dose were evaluated. The TNM classification 
of the International Union Against Cancer, 8th edition, 
was used. The depth of the lesion was evaluated by 
endoscopic ultrasound (EUS), and in cases where per-
forming EUS was difficult, we used endoscopic white 
light images for evaluation.
This study was approved by the ethical review 
board of the Tottori University Hospital (approval num-
ber 1508A024).
PDT treatment and surveillance
All PDTs were performed as inpatient procedures. 
Every case was performed in an endoscopic room under 
intravenous sedation. PDT was applied by intravenous 
administration of 40 mg/kg TS followed by diode laser 
irradiation at 100 J/cm2, six hours later. On the next day, 
if the treatment efficacy, assessed by ischemic changes, 
was observed to be insufficient on endoscopy, additional 
laser irradiation was performed.
After photosensitizer administration, all patients 
avoided direct sun exposure and stayed in a room main-
tained at less than 500 Lux. The duration of hospital 
stay after PDT was set at two weeks, provided there 
were no complications related to PDT. The endoscopic 
examination was repeated regularly after 1–2 weeks 
to evaluate the response until L-CR was confirmed. 
Computed tomography (CT) was used to evaluate dis-




Between January 2016 and December 2019, a total 
of 8 patients (10 lesions) with ESCC who had local 
failure after CRT (n = 7) or radiotherapy (RT) (n = 1) 
were studied. The patients included seven men and 
one woman, with ages ranging 63–82 years. The CRT 
regimen was standardized and comprised cisplatin (70 
mg/m2/day 1) and 5-fluorouracil (700 mg/m2/day 1 to 4) 
with concomitant RT of 54–60 Gy. The tumor location 
was the upper esophagus in one, middle esophagus in 
four, and lower esophagus in four patients. The baseline 
clinical stages before CRT or RT were stage I in one, 
stage II in three, stage III in three, and stage IVA in one 
patient (Table 1).
Efficacy and safety
The details of the procedure and treatment efficacy of 
TS-PDT are summarized in Table 2. There were four 
cases of recurrence after achieving CR with CRT/
Table 1. Characteristics of the patients who underwent PDT at the Tottori University Hospital between January 
2016 and December 2019
Case No Age Gender Initial Treatment Histology Location TNM
1 68 M CRT SCC Mt II
2 63 M CRT SCC Mt III
3 74 M CRT SCC Lt II
4 80 F CRT SCC Mt, Lt III
5 73 M CRT SCC Lt IVA
6 69 M CT, RT SCC Mt II
7 68 M CRT SCC Lt I
8 82 M CRT SCC Ut III
CT, Chemotherapy; CRT, chemoradiotherapy; F, female; Lt, lower thoracic esophagus; M, male; Mt, middle thoracic esophagus; PDT, 
photodynamic therapy; RT, radiotherapy; SCC, squamous cell carcinoma; TNM, TNM stage (UICC 8th) before PDT; Ut, upper tho-
racic esophagus.
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RT, and four residual lesions following CRT in four 
patients. Seven patients had one lesion and one patient 
had two lesions. The T stage on endoscopic assessment 
before TS-PDT was T1 in 6 patients (2 T1a lesion, and 
6 T1b lesion) and T2 in 2 patients (only one patient had 
a total of three lesions: one T1a and two T1b lesions). 
The two lesions of T1a had fibrosis in the submucosa 
after endoscopic treatment or radiation therapy, and 
endoscopic treatment was judged to be difficult. None 
of the patients had lymph node or distant metastasis 
on enhanced systemic CT evaluation before TS-PDT. 
The total irradiation dose was 600J (range, 300–800J). 
Seven patients achieved L-CR and the L-CR rate was 
87.5% (7/8). In the patient with no CR, an ulcer was 
observed at the laser-irradiated site two days after 
TS-PDT; however, the residual tumor after CRT did not 
disappear and persisted even two months after TS-PDT 
(Fig. 1). A representative case of a patient who achieved 
CR is shown in Fig. 2. This case had no recurrence after 
three years of follow-up (Fig. 2).
There were three adverse events, including steno-
sis, pain, and fever after TS-PDT. The fever and pain 
were grade 1 in all the cases according to CTCAE, 
and most of them recovered within a day. Two patients 
underwent endoscopic balloon dilation due to esopha-
geal stenosis, one of whom needed an intravenous drip 
on admission due to the stenosis (CTCAE grade 3). 
Perforation and skin phototoxicity were not observed in 
this study. There were no treatment-related deaths.
The median follow-up period was 30 months (range, 
14–47 months). The seven patients who achieved L-CR 
are on follow-up at the outpatient clinic till date. The 
patient who did not achieve CR (non-CR) had difficulty 
ingesting orally due to tumor growth 3 months after 
TS-PDT. After that, the patient continued chemo-
therapy, however died of disease progression 14 months 
after TS-PDT. The median overall survival (OS) was 
unpredictable in all patients. The 2-year OS was 87% 
(Fig. 3).
DISCUSSION
This study examined the results of the first eight cases 
of TS-PDT in our institution after its introduction. This 
was also the first application of TS-PDT in the Chugoku 
district of Japan. There were no treatment-related deaths 
in our study, and TS-PDT was observed to be effective 
as a salvage treatment option for local failure after CRT 
for ESCC, in line with the few prior reports.
Table 2. The details of the procedure and efficacy of PDT











1 Recurrence 1 T1b 1/4–1/2 500 L-CR Fever, pain, stricture
2 Recurrence 1 T1b 1/4–1/2 700 L-CR Pain, stricture
3 Recurrence 1 T1b < 1/4 350 L-CR –
4 Residual 3 T1a, T1b, T1b 1/4–1/2 800 L-CR Fever
5 Recurrence 1 T1a 1/4–1/2 700 L-CR Fever
6 Residual 1 T1b < 1/4 300 L-CR Pain
7 Residual 1 T2 1/4–1/2 800 L-CR –
8 Residual 1 T2 1/4–1/2 500 non-CR –
L-CR, local complete response; PDT, photodynamic therapy.
Fig. 1. Endoscopic images of the patient with non-CR after PDT. (a) Residual lesion detected after chemoradiotherapy. (b) Two days 
after PDT, ischemic changes were observed at the laser-irradiated site. (c) Persistence of lesion two months after PDT. CR, complete 
remission; L-CR, Local complete remission; PDT, photodynamic therapy.
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We examined for possible major complications of 
the procedure, including esophageal stricture, bleeding, 
perforation, and skin phototoxicity. Bleeding and per-
foration were not encountered in our cases. Esophageal 
stricture was the most frequent complication (2/8, 25%). 
In both the cases, multiple endoscopic balloon dilata-
tions had to be performed. The incidence of esophageal 
stricture after TS-PDT is reported to be around 
7.7–26.5%,14, 16 and in these reports, esophageal stricture 
was effectively treated by endoscopic balloon dilatation. 
Skin phototoxicity, often associated with PS-PDT, was 
not observed in our study. It has been proven in a study 
conducted at our institution that TS-PDT outperforms 
PS-PDT in terms of safety, especially regarding skin 
phototoxicity.16
In this study, the L-CR rate was significantly high 
(7/8, 87.5%). Of these, T1 cases achieved 100% (6/6) 
L-CR, while T2 cases had 50% L-CR (1/2). These 
results are similar to those of previous reports. Yano et 
al. have reported that the L-CR rate of T1 failure lesions 
Fig. 2. Representative case of L-CR after PDT, endoscopic images. (a) Residual lesion detected after chemoradiotherapy. (b) Two days 
after PDT, ischemic changes observed at the laser-irradiated site. (c) Four weeks after PDT, deep ulceration was observed at the site. 
(d) CR was achieved 10 weeks after PDT. (e) CR maintained three years after PDT. CR, complete remission; L-CR, Local complete 
response; PDT, photodynamic therapy.
Fig. 3. Survival curves for the enrolled patients after photodynamic therapy. PDT, photodynamic therapy.
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with TS-PDT was 100% (19/19), whereas that of T2 
failure lesions was 57.1% (4/7).14 Surgical resection has 
been traditionally performed in ESCC patients with 
local failure after CRT. Salvage surgical resection is 
considered as an option for curative treatment for local 
failure after CRT in patients with ESCC. However, 
there are drawbacks in terms of invasiveness and safety. 
Salvage esophagectomy has a significantly higher 
incidence of anastomotic leaks (39% vs. 7%) and longer 
hospital stay (29 days vs. 18 days) compared to planned 
esophagectomy.17 Swisher et al. also reported that 
there was no significant increase in operative mortality 
compared to planned esophagectomy (15% vs. 6%). It 
is important to recognize that this study was performed 
in a high-volume esophageal referral center with 
significant experience in high-risk esophagectomies.17 
Perioperative mortality is likely to be higher in hospitals 
with low-volume esophageal procedures.18
Regarding ER, Hattori et al. reported that the 
overall survival rate of patients treated with salvage ER 
for locoregional failure after definitive CRT was 56% 
at 3 years.9 From a technical point of view, salvage ER 
is difficult and at risk of incompleteness if the residual 
tumor extends deeper than the submucosa.11
There are few reports on the long-term results 
of PDT. Amanuma et al. reported the 2-year OS rates 
were 79%.16 In our study of a small number of patients, 
2-year OS rates was 87%, which is a good result. In 
particular, all patients with T1 survived, suggesting that 
PDT may be an effective treatment in the long term. 
We consider TS-PDT to be superior to salvage surgical 
resection since it is less invasive and technically easier 
to perform than salvage ER. Furthermore, it needs to 
be highlighted that an appropriate follow-up schedule 
after CRT is necessary for the early detection of local 
failures.
This study has several limitations. It was a single-
center retrospective study with a small sample size. 
However, we need to consider that the number of ESCC 
patients with local failure after CRT is limited to small 
cohorts, particularly those who underwent TS-PDT.
In conclusion, we opine that salvage TS-PDT is a 
safe and effective treatment for local failure after CRT 
in patients with ESCC. TS-PDT represents a promising 
treatment option, and we expect more patients with 
ESCC to benefit from TS-PDT hereon.
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